Head-To-Head Review: ThermoGenesis (THMO) and The Competition

ThermoGenesis (NASDAQ:THMO) is one of 156 public companies in the “Medical Devices” industry, but how does it contrast to its rivals? We will compare ThermoGenesis to related companies based on the strength of its earnings, institutional ownership, risk, profitability, analyst recommendations, dividends and valuation.

Profitability

This table compares ThermoGenesis and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ThermoGenesis	-153.43%	-4,838.39%	-107.53%
ThermoGenesis Competitors	-310.26%	-129.13%	-20.87%

Analyst Recommendations

This is a summary of current ratings and price targets for ThermoGenesis and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ThermoGenesis	0	0	1	0	3.00
ThermoGenesis Competitors	382	1541	2118	99	2.47

ThermoGenesis currently has a consensus price target of $5.00, indicating a potential upside of 999,900.00%. As a group, “Medical Devices” companies have a potential upside of 197.36%. Given ThermoGenesis’ stronger consensus rating and higher probable upside, research analysts plainly believe ThermoGenesis is more favorable than its rivals.

Earnings and Valuation

This table compares ThermoGenesis and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ThermoGenesis	$9.61 million	-$17.98 million	0.00
ThermoGenesis Competitors	$935.97 million	$70.71 million	110.23

ThermoGenesis’ rivals have higher revenue and earnings than ThermoGenesis. ThermoGenesis is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

ThermoGenesis has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500. Comparatively, ThermoGenesis’ rivals have a beta of 0.88, suggesting that their average stock price is 12% less volatile than the S&P 500.

Insider and Institutional Ownership

5.8% of ThermoGenesis shares are owned by institutional investors. Comparatively, 30.2% of shares of all “Medical Devices” companies are owned by institutional investors. 78.0% of ThermoGenesis shares are owned by company insiders. Comparatively, 24.7% of shares of all “Medical Devices” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

ThermoGenesis rivals beat ThermoGenesis on 7 of the 13 factors compared.

About ThermoGenesis

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. The company provides medical device products for automated cell processing. Its clinical bio-banking applications include AXP II Automated Cell Separation System, an automated fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. The company’s point-of-care applications include XP Point-of-Care System, an automated, fully closed, sterile system that allows for the rapid and automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; and PXP-1000 System, an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. Its cell processing products comprise X-Series products for general laboratory use, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The company also provides contract development and manufacturing services for cell and cell-based gene therapies. It markets and sells its medical device products through independent distributors, as well as direct to end-user customers. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.